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Introduction

'
The measurement of arginine-vasopressin, the antidiuretic hormone, in plasma and urine by radioimmunoassay has now been achieved by a number of authors using different methods. The reported values of mean plasma AVP'') concentration have varied from less than 0-5 to 4.0 ng/l in water-loaded subjects and from 3.7 to 18.0 ng/l in mildly dehydrated subjects. In contrast, the values reported for urinary AVP excretion rate are generally less variable. The antibodies used in these assays have usually only been characterized with respect to their cross-reaction with the more commonly occurring analogues of AVP, particularly oxytocin and lysine-vasopressin (Beardwell, 1971 ; Husain, Fernando, Shapiro, Kagan & Glick, 1973 ; Skowsky, Rosenbloom & Fisher, 1974 ; Robertson, Mahr, Athar & Sinha, 1973 ; Morton, Padfield & Forsling, 1975; Edwards, 1971 ; Oyama, Kagan & Glick, 1971 ; Fressinaud, Corvol & Menard, 1974 ; Miller & Moses, 1972; Czemichow, Merkelbach & Vallotton, 1975 ; Merkelbach, Czernichow, Gaillard & Vallotton, 1975) .
Previous authors (Chard, 1973 ; Czernichow, Reinharz & Vallotton, 1974) have discussed the production of antisera to different antigenic sites in AVP, and the implication if these sites are different from those responsible for biological activity. However, the importance of the immunological identity of antisera to AVP in radioimmunoassay has never been demonstrated. (Table 1) . Sandoz S.A. (Basle, Switzerland), gave 2-phenylalanine-8-lysine-vasopressin (Octapressin) and oxytocin. Dr Gary Robertson, University of Indiana, U.S.A., provided the 8-arginine-vasotocin. Sodium thioglycollate was purchased from British Drug Houses Ltd (Poole, Dorset, U.K.) and diphenyl carbamyl chloride-treated trypsin from Sigma Ltd, London.
Methods
Materials
Anribody production. Crystallized bovine plasma albumin for the conjugation of AVP was obtained from Armour Pharmaceutical Co. Ltd (Eastbourne, Sussex, U.K.), l-cyclohexyl-3-(2-morpholinoethyl)-carbodi-imide and 1-(3-dimethylarninopropyl)-3-ethylcarbodi-imide from Aldrich Chemical Co. Ltd, London; complete Freunds adjuvant was from Difco Laboratories, Detroit, Michigan, U.S.A.
Extraction and assay. The extraction of AVP from plasma and urine utilized Florisil (100-200 mesh; Koch-Light Ltd, Bucks., U.K.), and AnalaRgrade acetone (British Drug Houses Ltd), which was redistilled before use. Phosphate buffer (0.5 mol/l) was prepared by adjusting Na2HP04 (0.5 mol/l) to pH 7.5 with KH2P04 (0.5 mol/l), this being diluted with distilled water to prepare 0.05 mol/l phosphate buffer. Tris-HC1 buffer (0.05 mol/l) was prepared by dissolving 0-1 mol of Tris in 500 ml of distilled water, adjusting to pH 7.5 with HCI (0.1 mol/l) and finally diluting to 2 litres with distilled water. Materials for these buffers were obtained from British Drug Houses Ltd. Barbitoneacetate buffer (0.05 mol/l), pH 8-6, was purchased from Oxoid Ltd (London) and Norit charcoal (SXI grade) for separation of antibody-bound from free AVP was from British Drug Houses Ltd. Disposable polystyrene tubes (8 mm x 62 mm) for the antigen/ antibody reaction and for radioactivity counting of supernatant from the charcoal separation of bound and free 12?-AVP were obtained from Luckham Ltd, U.K. NaiZ5I (code IMS.30, The Radiochemical Centre, Amersham, Bucks, U.K.), was used for labelling AVP.
Plasma and urine osmolalities were measured with an Advanced Osmometer model 64.31 (Fisons Scientific Apparatus Ltd, Loughborough, Leics., U.K.).
Radioimmunoassay of arginine-vasopressin
527
Antibody production
Antibodies were raised in three rabbits. Crystallized bovine plasma albumin (5 mg) was dissolved in 1 ml of a solution containing 375 pg of AVP, and either 0.125 mmol of l-cyclohexyl-3-(2-morpholinoethy1)carbodi-imide (antiserum R1, Dutch rabbit and antiserum R4, New Zealand White rabbit), or 0-20 mmol of 1-(3-dimethylaminopropyl)-3-ethylcarbodi-imide (antibody R2, Dutch rabbit) was added with rapid mixing. After 4 h at room temperature each solution was treated with the same amount of the appropriate carbodi-imide as before, mixed, and then left at room temperature overnight. Each rabbit was injected intramuscularly with 250 pl of the resulting mixture homogenized in an equal volume of complete Freunds adjuvant. Rabbits were injected at intervals of 14 days and blood was collected from a marginal ear vein 10-14 days after the fifth injection. Three months was allowed before the injection schedule was repeated.
Iodination of A VP
Iodination was carried out by a modification of the method of Greenwood, Hunter & Glover (1963), with 0.5 mCi of NaiZsI (specific radioactivity 12-17 mCi/pg) in 5 p l , mixed with 10 p1 of phosphate buffer (0.5 mol/l), pH 7.5. After addition of 2 pg of AVP in 5 p1 of distilled water, the reaction was started by adding 20 pg of chloramine T in 5 p1 of phosphate buffer (0.05 mol/l), pH 7.5. After 15 s the mixture was diluted with 1 ml of Tris-HC1 buffer (0.05 mol/l), pH 7.5, and transferred immediately to a DEAE-Sephadex A25 column (18 cm x l cm) equilibrated in Tris-HC1 buffer, pH 7.5. The same buffer was used for elution and 0.5 ml fractions were collected.
Extraction of A VP from plasma and urine
Plasma and urine samples were stored at -20°C and usually extracted within 1 week of collection on Florisil by a modification of the methods of Beardwell (1971) and Morton et al. (1975) . The Florisil was first washed several times with distilled water to remove fine particles and then dried at 200°C for 48 h. Each plasma or urine sample (5-10 ml) was mixed with 100+_10 mg of Florisil for 30 min at room temperature, the supernatant then being discarded. The Florisil was washed briefly with distilled water (10 ml) and then mixed with acetone (5 ml) for 30 min, the washings being discarded. After a further washing with 10 ml of distilled water and twice with 5 ml of HCl (0.2 mol/l) the AVP was eluted from the Florisil into 2 ml of 10% distilled water in acetone, with mixing by repeated inversion of the tubes for 30 min. After centrifugation, the eluate was transferred to a small siliconized glass test tube. The Florisil was then washed again with distilled water (5 ml), followed by 5 ml of HCI (0.2 mol/l) before being eluted a second time with 2 ml of 10% distilled water in acetone. The eluates were combined and evaporated to dryness in the siliconized glass test tube in a water bath at 40°C under a stream of air. The dried extracts were stored at -20°C until assayed.
%AVP from plasma. Elution of radioactivity was accomplished by acidified aqueous acetone, neither dilute acid nor aqueous acetone being effective alone. In this way 60-70% of the adsorbed radioactivity was eluted in the first aliquot of aqueous acetone and the remaining 3040% in the second aliquot. This further recovery of radioactivity only occurred if the Florisil was reacidified after the first elution. Pretreatment of Florisil with strong acid abolished its ability to adsorb AVP from plasma, although it could still adsorb AVP from a dilute buffer.
The Florisil completely adsorbed
Assay
Barbitone-acetate buffer (0.05 mol/l), pH 8.6, containing human albumin (1.25 g/l) was used in the assay. Standard curves were prepared from a stock standard of AVP diluted with equal volumes of buffer so that a range of ten standards, in doubling dilutions from 256 pg to 0-5 pg in 0.2 ml of buffer, were obtained. Extracts of plasma and urine were reconstituted in 1.0 ml of buffer and 0.01-0.4 ml was taken for assay. Plasma extracts were assayed in duplicate and urine extracts in triplicate. Each assay tube was made up to 0.6 ml with buffer, and 0-2 ml of antiserum at a dilution of 1:15 OOO for R2 or 1 :20 OOO for R4 was added. Each assay included tubes without native AVP ('antibody control') and with buffer alone ('damage control'). After equilibration of antibody and native AVP at 4°C for 3 days each tube had 1000-1500 c.p.m.
of 1251-AVP (1-10 pg) added in 20 pl of buffer. The reaction continued at 4°C for 3 days before free AVP was separated from antibody-bound AVP with plasma-coated charcoal.
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Norit charcoal (SXl grade, 1 g) was dispersed in 100 ml of Tris-HC1 buffer, pH 7.5, and 10 ml of human or equine serum or plasma was added. This mixture was stirred continuously and when it had been cooled to 4"C, 1 ml was added to each of the assay tubes, which were then mixed and centrifuged within 10 min at 2000 g and 4°C for 5 min, the supernatant from each tube being decanted. The lz5I-AVP not bound to antibody became adsorbed to the charcoal. Results were expressed as the ratio of antibody-bound (supernatant) to free l2 51-AVP (bound to charcoal). Each charcoal and supernatant fraction was counted for radioactivity for 10 min in an automated deep-well gamma spectrometer (Intertechnique CG30-300) with 55% counting efficiency. In the absence of antibody approximately 5% of the radioactivity remained in the supernatant (damage control). The batch of lZ5I-AVP was rejected when the damage increased to 10%.
Chemical and enzymatic modifications of A VP
The 1-6 disulphide bond was cleaved by incubating 1 pg of AVP with 1 ml of sodium thioglycollate solution (either 0.1 moll1 or 0.4 molll) for 24 h at room temperature. An aliquot of the solution was diluted 2000-fold in assay buffer before the remaining immunoreactive material was estimated in the standard radioimmunoassay with antisera R2 and R4.
The 8-9 arginine-glycineamide peptide bond was hydrolysed by treating 1 pg of AVP with 0.3 mg of trypsin (7500 benzoylarginine ethyl ester unitslmg : 1 unit gave A E OQOl/min at 253 nm in a volume of 3.2 ml at pH 7.6 at 25"C, diphenyl carbamyl chloride-treated) in 1 ml of Tris-HC1 buffer, pH 7.5, at 37°C. Samples of the digest were taken at 0, 10 and 60 min, diluted 2000-fold in assay buffer and assayed for immunoreactive material. Hydrolysis of the 1-2 half-cystinetyrosine peptide bond occurred when 1 ml of full-term pregnancy plasma was incubated with 1 pg of AVP at 37°C. Samples were taken at 0, 5,20 and 60 min.
Since the kidneys are a major site of biological degradation of AVP, a rat kidney homogenate was used to digest AVP. Two rat kidneys were homogenized in KCI (0.15 mol/l) in a Potter-Elvehjem homogenizer (167 mg wet wt of tissuelml of homogenate). The kidney homogenate (1 ml) was diluted to 83 ml with Tris-HC1 buffer, pH 7-5, and 1 ml was used to digest 1 pg of AVP at 37°C. Aliquots (0.1 ml) of the digest were taken at 0, 30 and 120 min. Each aliquot was mixed with 0-5 ml of acetone, centrifuged, and the supernatant transferred to a siliconized glass test tube for evaporation to dryness under a stream of air at 40°C. The reconstituted residue was assayed for immunoreactive material.
Physiological studies
Blood and urine samples were collected from five normal subjects under normal conditions at 10.00 hours. Subjects were then given an acute water load of 25 mllkg body weight, which was maintained by drinking a volume of water equal to that lost in the urine. When peak urine flow rate had been achieved blood and urine samples were collected. Dehydration experiments were carried out by depriving subjects of water for 15 h from 19.00 until 10.00 hours the following morning and for 22-24 h from 19.00 until 17.00-19.00 hours the next day. All samples were collected after the subjects had been sitting quietly for 30-45 min. Venous blood was taken into plastic tubes containing lithium heparin (12.5 i.u./ml of blood). The tubes were chilled at 4°C and centrifuged for 15 min at 2000 g. Plasma and urine were stored at -20°C in plastic tubes. Osmolality was determined by freezingpoint depression.
Results
Antisera to A VP
The specificity of antisera R1 and R2 was very similar but different from that of antiserum R4. Antiserum R2 was more sensitive than R1. The latter antiserum was not studied further.
Zodination of AVP
When the iodination reaction mixture was chromatographed on DEAE-Sephadex A25 a large radioactive peak was eluted, followed by a smaller peak of variable size. More than 90% of the radioactivity in all fractions of both peaks could be bound by the antisera, indicating that this proportion of the radioactivity was 1z51-AVP. Assay with R4 of fractions on the ascending part of the main radioactive peak gave a specific radioactivity of 20-50 mCi/mg, and a value of 100-200 mCi/mg was obtained for fractions from the descending part of the same peak. The specific radioactivity for labelled hormone in the second peak, assayed with R4, was 350-700 mCi/mg, and this may have been 2-(2,5-di-iodotyrosine)-AVP. The specific radioactivities of the same fractions assayed with R2 were 40-100, 250-500 and 1000-2000 mCi/mg respectively.
One or two fractions from the apex of the first peak were divided into 50 j 11 aliquots and stored at -20°C. An aliquot was diluted as required for use in an assay.
Assay sensitivity
In the absence of unlabelled hormone ('antibody control'), the ratio of antibody-bound labelled hormone to free labelled hormone was from 1.0 to 1.2 for R2 and from 0.8 to 1.0 for R4. A typical standard curve obtained with antiserum R2 is shown in Fig. 1 . The limit of detectability for the assay was taken as a 10% fall in the bound to free ratio, which corresponded to 1 pg for the assay with antiserum R2 and 4 pg for the assay with R4. 
Extraction of A VP from plasma and urine
The recovery of AVP from plasma was determined by extracting two aliquots of a sample of plasma, one of which had been enriched with AVP. The recovery of 100 pg of AVP from 8-10 ml of plasma was 93% (SD 5%, n = 10). The recovery of 20 pg of AVP was similar. The recoveries of 100 pg of AVP from urine (800-1000 mosmol/l) and from Tris-HC1 buffer, pH 75, were also similar. The values obtained from aliquots of a plasma sample assayed over 6 months were 1.4 ng/l (SD 0.2, n = 12) with R2 and 8.7 ng/l (SD 1.7, n = 15) with R4. In addition to this pool of plasma, which showed no fall in AVP concentration during 6 months' storage at -2O"C, six other plasma samples showed no fall in measurable AVP, between 2 days after collection and 4 weeks later (when stored at -20°C). AVP in urine was found to be equally stable. Since the first extractions were carried out after 2 days' storage, it is possible that the rapid initial fall in AVP concentration in stored plasma that has been reported by Robertson et al. (1973) may have already occurred. However, the plasma AVP concentrations reported in the present case were stable at the time of assay.
No AVP was detected in the urine from some water-loaded subjects and it was therefore inferred that non-specific interference did not arise in the extraction procedure itself. The material extracted from plasma and urine and measured in the assay was found to have a parallel dilution curve to standard AVP. Incubating the extracted material with sodium thioglycollate (0.2 mol/l) destroyed all the immunoreactive material in both the plasma and urine extracts, as measured by antiserum R2, but none of that measured by antiserum R4.
Specifcity of antisera
Various amounts of the synthetic peptides,
vasopressin, 2-phenylalanine-8-lysine-vasopressin, oxytocin, 8-arginine-vasotocinY l-deaminod-carba-AVP, pressinoic acid amide and Pro-Arg-Gly-NH2 were incubated in the assay for AVP in place of unlabelled AVP. All these materials when reacting in the assay gave dilution curves parallel to that of AVP. Thus, for ease of comparison, the results for each peptide could be converted into the amount necessary to give a displacement of labelled AVP equivalent to 1 pg of unlabelled AVP present in the assay (Table 1) . This also indicates the on the binding to antisera R2 and R4 Amounts (Ijfg) of native AVP were incubated with 1 ml of trypsin solution (0.3 mg/ ml) in Tris-HC1 buffer (0.05 mol/l), pH 7.5, or 1 ml of full-term pregnancy plasma, or 1 ml of a rat kidney homogenate (2 mg wet wt. of tissuelml of homogenate), in Tris-HCI buffer, pH 7.5, at 37OC. The disappearance of immunoreactive material during each incubation was followed by the use of antisera R2 and R4. Amounts (1 jfg) of native AVP were also treated with 1 ml of sodium thioglycollate solution (either 0.1 mol/l or 0.4 mol/l) for 24 h and the effect on the immunoreactivity to antisera R2 and R4 was determined. The influence of pH on the binding of lZ5I-AVP to antisera R2 and R4 was also investigated. inadequacy of 'parallelism' in the assay as a criterion for AVP being the immunoreactive material. Increasing concentrations of sodium thioglycollate progressively decreased the immunoreactivity of AVP to antiserum R2 until, with sodium thioglycollate at 0.4 mol/l, only 15% remained. The reaction of antiserum R4 was unaffected by reduction of AVP ( Table 2 ). In addition, the effect of thioglycollate on the binding of pressinoic acid amide to R2 was identical with its effect on AVP, that is, binding was reduced to l0-15% of the original.
The binding of 1251-AVP to R2 was not affected by changes in pH from 8.6 to 6.5, but the binding to R4 decreased from 50% to 37% over this pH range ( Table 2 ). The effect of enzymatic digestion of AVP on the immunoreactivity to R2 and R4 is also shown in Table 2 . Antiserum R4 appears to be less sensitive to changes in the structure of AVP brought about by natural legradative processes.
Physiological studies
On unrestricted food and water intake, five normal subjects at 10.00 hours had mean values of plasma osmolality of 276 (SD 3.5) mosmol/kg and AVP concentration of 0.57 (SD 0-20) .ng/l with antiserum R2. The corresponding value of plasma AVP concentration measured with R4 was 6.1 (SD 1.0) ng/l. After 15 h dehydration overnight these values did not change significantly, plasma osmolality being 276 (SD 1.9) mosmol/kg and plasma AVP 0.83 (SD 0.57) ng/l by R2 and 6-2 (SD 0.9) ng/l by R4. Changes in plasma AVP concentration are shown in Fig. 2 ; some subjects showed marked rises in plasma AVP concentration measured by R2 although overall the difference between the groups was not significant. Continuing the dehydration for a further 7-9 h resulted in a significant rise in plasma osmolality to 280 (SD 1.6) mosmol/kg (P<O.O5), Timed collections of urine were made simultaneously with the collection of blood during the above physiological manoeuvres and the excretion rates of AVP were measured with antisera R2 and R4. The pattern of significant changes was identical with that observed with changes in plasma AVP concentration. Thus R2 did not reflect a significant change in AVP excretion rates in subjects on unrestricted food and water intake and after 15 h dehydration overnight. The mean values were 40.9 (SD 17.6) pg/min and 30.9 (SD 14.0) pg/min respectively. After a further 7-9 h dehydration the value rose significantly to 170.4 (SD 102.6) pg/min (P = 0.01 by Wilcoxon's test). The AVP excretion rate in subjects loaded with 25 ml of water/kg body weight fell to 4.0 (SD 3.1) pglmin, which was significantly lower (P = 0.01 by Wilcoxon's test) than in the other three states (Fig. 3) . The corresponding values obtained with R4 were 51.7 (SD 11.6) pg/min in subjects on unrestricted food and water, 41.8 (SD 16.9) pg/min in subjects after 15 h dehydration, 173.4 (SD 100.7) pglmin after 22-24 h dehydration and 59-4 (SD 33.5) pglmin after a water load of 25 When the plasma AVP concentration measured by R2 is considered as the independent variable with urine osmolality as the dependent variable, a very significant correlation (r = 0.81, P<O*Ool) is obtained if the plasma AVP concentration is expressed as its logarithm (Fig. 4) . The equation of the regression line is urine osmolality = 637.log- Plasma AVP concentration and AVP excretion rate are very significantly correlated (r = 0.965, P < 0.001). However, the correlation is improved by correcting the AVP excretion rate for the total osmolar clearance (Fig. 5) . The equation of the line is urine AVP = 33.8blasma AVP] -4.7 (r = 0.97,
Discussion
A number of antisera to AVP have now been reported and some of these have been used in radioimmunoassays. It has recently been shown (Czernichow et al., 1974) that it is possible to raise antisera to AVP with different immunological specificities. The present work supports this observation and shows the consequences for the measurement of AVP in plasma and urine.
Sensitiuity and reproducibility of the assay
The overall sensitivity of an assay for AVP, in terms of plasma and urine concentrations, is dependent on the amount of plasma or urine that is extracted and the recovery of the peptide during this procedure. Our principal modification of the extraction procedure from that of Morton et al. (1975) was to elute adsorbed AVP from the Florisil. We reacidified the glass beads before a repeated aqueous acetone elution, so improving recovery of AVP from the 60% (SD 6.9%, n = 24) reported by Morton et al. (1975) to 93% (SD 5%, n = 10).
It is unlikely that Florisil is specific for the adsorption of AVP. The discrepancy observed in the amount of immunoreactive material extracted from plasma and urine and identified by R2 and R4 suggests that material other than native AVP is extracted. However, since the material measured by R2 is destroyed by incubation with sodium thioglycollate solution, this is unlikely to be anything other than native AVP. Certainly, R2 has a very low reactivity towards other peptides similar to AVP that may be affected by thioglycollate (oxytocin, pressinoic acid amide and even AVP with its C-terminal glycineamide residue removed; Table 1 ). It is not surprising that thioglycollate reduction of the material extracted from plasma and urine does not affect its binding to R4 since native and thioglycollate-reduced AVP bind equally well to this antiserum (Table 2) . However, the plasma and urine extracts give dilution curves parallel to native AVP in the assays with both antisera R2 and R4. Since R4 is measuring material other than native AVP in the extracts, this result, and the parallel dilution curves obtained with peptide analogues and fragments of AVP, show that parallel dilution curves are not proof of identity.
Structure of A VP and its antigenic sites
Neurohypophyseal peptide structure can be represented by a model (Fig. 6) , in which the hexapeptide ring is overlaid by the tripeptide tail (Walter, Schwartz, Darnel1 & Urry, 1971) . With this structure of AVP, the observed cross-reaction characteristics of antisera R2 and R4 (Table 1) can be explained if the binding site on AVP for R2 comprises the peptide residues at positions 1, 2, 3 and possibly 4, 6 and 9, whereas the binding site for R4 includes residues 6, 7, 8 and possibly 5.
Thus the binding site for R2 will be greatly affected by reduction of the disulphide bond and opening the peptide ring. Conversely, the stereochemistry of the R4 binding site is largely determined by the proline residue at position 7. This can explain why thioglycollate-reduction of AVP destroys binding to R2 but does not affect binding to R4. Although the binding to R2 was not totally destroyed (Table 2) , the decreased binding with increasing thioglycollate concentration could reflect the equilibrium nature of the reaction between sodium thioglycollate and AVP and the fact that R2 does not bind with AVP when the disulphide bond has been reduced and the peptide ring opened. Thioglycollatereduction of AVP is known to destroy its biological activity (Van Dyke, Chow, Greep & Rothen, 1942) , and this test clearly demonstrates a separation of biological and immunological activity with antiserum R4. Therefore the values for AVP concentration obtained with R4 must be interpreted with caution whereas the values obtained with R2 may be accepted with greater confidence.
Antiserum R4 distinguishes oxytocin from AVP more strongly than does R2 (Table 1) T. H . Thomas and M. R. Lee similar characteristics at position 3. As confirmation of this, AVT, which differs from AVP only by the presence of an isoleucine residue at position 3, is not distinguished from AVP by R4, but is distinguished by R2, even more than oxytocin. This may result from the tripeptide 'tail' being held more tightly across the ring when a leucine residue is in position 8, so improving binding to R2.
The hexapeptide ring (pressinoic acid amide) and the tripeptide tail (Pro-Arg-Gly-NH,) were examined separately (Table 1) . Antiserum R2 bound predominantly with the ring structure and was insensitive to the tripeptide tail (binding ratio 1 : < 0.008) whereas R4 bound hardly at all with the ring but very well with the tripeptide tail (binding ratio <0.004:1). However, R2 does not bind as well to the isolated hexapeptide ring as it does to native AVP and, therefore, the tripeptide tail must either influence the conformation of the ring or be partly included in the binding site of R2. The latter may seem unlikely since R2 does not detect ProArg-Gly-NH2 at all. Further evidence on the involvement of the tripeptide tail in the binding site of R2 is provided by the digestion of AVP with trypsin, which will preferentially hydrolyse the peptide bond involving the carboxyl group of arginine, thus removing the glycineamide residue in position 9. This modification to AVP almost abolishes binding with R2 but is virtually without effect on the binding with R4 ( Table 2 ) .
The behaviour of the antisera with the other analogues in Table 1 is more difficult to explain since changes in more than one position in AVP are involved. For example, R4 will detect a change from L-arginine at position 8 in l-deamino-8-D-argininevasopressin but the alteration in overall conformation of the tripeptide tail will probably also affect the binding to R2, in addition to the loss of the N-terminal amino group. Perhaps the most interesting analogue is l-deamino-6-carba-AVP, for which both antisera show a greater affinity. The substitution of a methylene residue for the sulphur atom at position 6 must give rise to this effect with R4, but R2 will also detect the N-terminal deamination. N-terminal deamination has also been shown to increase antidiuretic potency in synthetic analogues and this may be as a result of improved receptor binding (Manning, Balaspiri, Judd, Acosta & Sawyer, 1974) .
Since iodination of the tyrosine residue at position 2 will resiilt in the phenolic group becoming much more acidic, changes in pH from 6.5 to 8.6 will only have a significant effect on the ionization of the arginine residue at position 8. As expected, these changes in pH affect the binding of lZ5I-AVP to R4 but are without effect on the binding to R2 ( Table 2 ) .
The substitution of an iodine atom at position 2 in AVP should affect the binding to R2. The reduced affinity of R2 for 1251-AVP, when compared with native AVP, would account for the different apparent specific radioactivities of the labelled peptide calculated by assay with R2 and R4 and a native AVP standard. As this method does not give an independent measurement of specific radioactivity, neither value can be regarded as true, but since changes in AVP at position 2 do not appear to affect binding to R4, values of specific radioactivity obtained with this antiserum are believed to be the most reliable. In addition, the lower affinity of R2 for lZ5I-AVP than for native AVP will result in the greater sensitivity of the assay with this antiserum compared with the use of R4.
Since antisera R1 and R4 of different specificity were obtained with the same carbodi-imide reagent, whereas antiserum R2, of similar specificity to R1, was raised with a different wbodi-imide reagent, it seems unlikely that the carbodi-imide reagent used to conjugate AVP to bovine plasma albumin greatly influences the specificity of the antiserum obtained,
Physiological studies of AVP in inail
The plasma concentration of AVP given by R4 was found to be much greater than that given by R2. Significant changes in plasma and urine osmolality were accompanied by significant changes in the plasma AVP concentration and AVP excretion rate when measured with R2. This was not found when R4 was used to measure AVP. Most of the material measured by R4 was not sensitive to changes in plasma osmolality, and in most cases this masked the changes in active AVP, which occurred at much lower concentrations, as measured by R2. Plasma AVP concentration measured by R2 is very significantly correlated with urine osmolality in a typical dose-response curve (Fig. 4) . Thus at low concentrations of plasma AVP small increases in AVP concentration result in large increases in urine osmolality, but as the AVP concentration rises ever-increasing amounts are required to cause the same increment in urine osmolality. Antiserum R4 does detect would be expected that a signilicant correlation between plasma AVP concentration or urine AVP excretion rate and plasma or urine osmolality could be obtained.
Since plasma AVP concentration and urinary AVP excretion rate are very closely correlated, when measured by R2 (Fig. 5) , the AVP excretion rate is correlated with changes in plasma and urine osmolality in the same way as plasma AVP concentration. However, the correlation of plasma and urine measurements of AVP shown here only applies to the closely controlled physiological experiments involved. Many factors may influence urinary excretion of AVP (Robertson, 1974) , in addition to the plasma concentration, and we now have some evidence to support this view. The AVP excretion rate measured by R4 is not related to the plasma AVP concentration measured with R2 or R4, the changes in AVP excretion rate on acute water loading being very erratic. However, in contrast to plasma, where R2 and R4 gave values of AVP concentration in different ranges, in urine the values given by R2 and R4 were often quite similar, except in acute water loading. Particularly notable was the way in which AVP excretion rates measured by R2 and R4 became the same when subjects were dehydrated. This suggests that dehydrated subjects were only excreting native AVP in the urine whereas normally or overhydrated subjects were excreting native AVP as well as other R4-immunoreactive material, as R4 always gave a higher value than R2 for urine AVP in such cases.
The most reasonable explanation for the difference between the values of AVP concentration given by R2 and R4 is that R4 is also reacting with fragments from the degradation of AVP. Changes in the immunoreactivity of AVP during digestion with both pregnancy plasma and a rat kidney homogenate were detected by both R2 and R4 (Table 2) . However, R4 was less sensitive to the degradative changes than R2. This gives support to the hypothesis that natural degradation of AVP may lead to the production of fragments that will bind with R4 but not R2.
We now consider it essential for the reliability of an AVP assay that it should not detect thioglycollate-reduced material from plasma and urine.
-
